Stocks · Health care · Biological Products, (No Diagnostic Substances)

Taysha Gene Therapies, Inc.

TSHA Clue Score55
United States Fiscal year ends December CIK 0001806310 Results filed 11 Aug 2026

What the insiders did Net buying

Insider
Date
Role
Action
Shares
Price
Amount
Sukumar Nagendran
10 Jul 2026
President and Head of R&D
Sold on a plan
200,000
$6.24
$1.25M
Kamran Alam
24 Aug 2023
Chief Financial Officer
Sold on a plan
33,000
$2.33
$76.89K

What was left out

Form 4 filings counted 106
Amendments (4/A) skipped 1
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 2
Sales straight out of an exercise 5
Sales at will 36
Transactions with no price 0
Shares from compensation/vesting 14,986,465
Sales filed before the plan box existed 21
History held since 25 Sep 2020